524790.BO Stock Analysis
52
Avoid
Based on Eyestock quantitative analysis, 524790.BO`s fundamental data and valuation indicate an investment grade of Avoid at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Overvalued
Market cap $B
0.009
Dividend yield
0.33 %
Shares outstanding
8 B
Everest Organics Ltd. is a pharmaceutical company, which engages in the manufacture of bulk drugs. The company is headquartered in Hyderabad, Telangana and currently employs 400 full-time employees. The company is involved in manufacturing of bulk drugs, such as Omeprazole, Ciprofloxacin, Dichloroflurobenzene, Naproxen, Benzimadizole. The Company’s API’s products include Pantoprazole Sodium Sesquihydrate USP/BP/EP/IP, Esomeprazole Magnesium Trihydrate-USP/BP/IP/EP, Esomeprazole Magnesium Trihydrate-USP/BP, Esomeprazole Magnesium Dihydrate, Omeprazole Powder-USP / BP/ EP/IP, Omeprazole Magnesium-IP/EP/USP and others. Its intermediates products include 2-Mercapto-5-Methoxy Benzimidazole (Omeprazole-Benzimidazole), 2-Chloro-Methyl-3,5-Dimethyl-4-Methoxy Pyridine HCL (Omeprazole Chloro Compound), Ammonium Sulphate, Sodium Nitrite and others. Its products under development include Sitagliptin, Vildagliptin, Ilaprazole, N-(5-Amino-2-Methylphenyl)-4-(3-Pyridyl)-2-Pyrimidineamine (Imatinib Intermediate), Lanso Sulphide and others.